KemPharm, Inc.

kempharm.com

KemPharm, Inc.
KemPharm is a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs that are designed to be improved versions of widely prescribed, approved drugs.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

FAREVA AND APIJECT SIGN A LICENSING AGREEMENT TO CREATE A FRANCE-BASED 500M UNIT ANNUAL CAPACITY FOR SINGLE-DOSE PREFILLED VACCINE INJECTIONS

ApiJect Systems Corp. | December 10, 2021

news image

Fareva and ApiJect Systems, Corp. announced a 10-year licensing agreement to install three Blow-Fill-Seal production lines that when operational will be able to fill-finish more than 500 million doses per year of vaccines and other large molecule injectable drugs using ApiJect's innovative prefilled injector technology. Fareva intends to invest more than €50M for these three manufacturing lines, with support from the Government of France, through the "France Relance" industry ...

Read More

Business Insights

INVERSAGO PHARMA RAISES $95 MILLION CAD IN SERIES C FINANCING

Inversago Pharma Inc. | October 18, 2022

news image

Inversago Pharma Inc. a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, announced the completion of a Series C funding of $95 million CAD led by New Enterprise Associates. Additional new investors Forbion’s Growth Opportunities Fund and Amgen Ventures joined current investors including Forbion’s Ventures Fund IV Fonds de solidarité FTQ, Genesys Capital, AmorChem, JDRF T1D Fund and adMare BioInnovations in the financing round....

Read More

Pharma Tech

SIRONA BIOCHEM SIGNS INTERNATIONAL PARTNERSHIP AGREEMENT WITH WANBANG BIOPHARMACEUTICALS

Sirona Biochem Corp. | November 28, 2022

news image

Sirona Biochem Corp. announces that, subsequent to the LOI, Sirona and Wanbang Biopharmaceuticals have signed an expanded, international partnership agreement to collaborate on licencing Sirona’s SGLT2 inhibitor, TFC-039, as a pharmaceutical treatment in both animal and human health. The agreement adds human health to the partnership as a result of new licencing opportunities currently in due diligence. Wanbang and Sirona initially signed a licensing agreement for TFC-039, w...

Read More

Research

NRX PHARMACEUTICALS ANNOUNCES NEW FINDING FROM ZYESAMI™ (AVIPTADIL) PHASE 2B/3 CLINICAL TRIAL

NRx Pharmaceuticals | August 30, 2021

news image

NRx Pharmaceuticals announced an additional finding in its phase 2b/3 clinical trial investigating ZYESAMI™ (aviptadil) for the treatment of patients with acute Respiratory Failure due to Critical COVID-19. Previously announced results have focused on survival and recovery from respiratory failure at 60 days, and ZYESAMI's apparent role in preventing rise in the inflammatory cytokine IL-6, known as "Cytokine Storm." NRx's new analysis shows that patients tr...

Read More
news image

Pharma Tech

FAREVA AND APIJECT SIGN A LICENSING AGREEMENT TO CREATE A FRANCE-BASED 500M UNIT ANNUAL CAPACITY FOR SINGLE-DOSE PREFILLED VACCINE INJECTIONS

ApiJect Systems Corp. | December 10, 2021

Fareva and ApiJect Systems, Corp. announced a 10-year licensing agreement to install three Blow-Fill-Seal production lines that when operational will be able to fill-finish more than 500 million doses per year of vaccines and other large molecule injectable drugs using ApiJect's innovative prefilled injector technology. Fareva intends to invest more than €50M for these three manufacturing lines, with support from the Government of France, through the "France Relance" industry ...

Read More
news image

Business Insights

INVERSAGO PHARMA RAISES $95 MILLION CAD IN SERIES C FINANCING

Inversago Pharma Inc. | October 18, 2022

Inversago Pharma Inc. a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, announced the completion of a Series C funding of $95 million CAD led by New Enterprise Associates. Additional new investors Forbion’s Growth Opportunities Fund and Amgen Ventures joined current investors including Forbion’s Ventures Fund IV Fonds de solidarité FTQ, Genesys Capital, AmorChem, JDRF T1D Fund and adMare BioInnovations in the financing round....

Read More
news image

Pharma Tech

SIRONA BIOCHEM SIGNS INTERNATIONAL PARTNERSHIP AGREEMENT WITH WANBANG BIOPHARMACEUTICALS

Sirona Biochem Corp. | November 28, 2022

Sirona Biochem Corp. announces that, subsequent to the LOI, Sirona and Wanbang Biopharmaceuticals have signed an expanded, international partnership agreement to collaborate on licencing Sirona’s SGLT2 inhibitor, TFC-039, as a pharmaceutical treatment in both animal and human health. The agreement adds human health to the partnership as a result of new licencing opportunities currently in due diligence. Wanbang and Sirona initially signed a licensing agreement for TFC-039, w...

Read More
news image

Research

NRX PHARMACEUTICALS ANNOUNCES NEW FINDING FROM ZYESAMI™ (AVIPTADIL) PHASE 2B/3 CLINICAL TRIAL

NRx Pharmaceuticals | August 30, 2021

NRx Pharmaceuticals announced an additional finding in its phase 2b/3 clinical trial investigating ZYESAMI™ (aviptadil) for the treatment of patients with acute Respiratory Failure due to Critical COVID-19. Previously announced results have focused on survival and recovery from respiratory failure at 60 days, and ZYESAMI's apparent role in preventing rise in the inflammatory cytokine IL-6, known as "Cytokine Storm." NRx's new analysis shows that patients tr...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us